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Case Summary:
Demographic Details:
Mr. SF, male, South African was referred by his 
general practitioner 
A 26-year-old South African gentleman 
was referred to the Neurology Outpatient 
department due to occasional episodes of 
bilateral muscle weakness in the lower limbs. 
The attacks last for approximately 1 hour and 
may result in complete muscle paralysis. The 
severe attacks of bilateral lower limb paralysis 
are uncommon. The most severe attack he had 
ever experienced lasted for 19 hours when he 
was 19 years of age.
Mr. SF noticed that stress, carbohydrate-rich 
meals and exercise triggered recurrent attacks 
of muscle weakness. The patient’s grandfather, 
father and sister have been diagnosed with 
‘Familial Paroxysmal Hypokalaemic Paralysis’ 
(hypoKPP). The father had a positive genetic 
diagnosis from a muscle biopsy. Mr. SF believes 
that he has inherited the genetic condition, 
however, he was never tested for the mutation.
When the patient suffers an attack of muscle 
weakness, he takes potassium supplements and 
rests at home and symptoms resolve. 
Presenting Complaint:
Mr. SF presented to the Neurology Outpatient 
department with recurrent episodes of bilateral 
lower limb weakness and paralysis. The patient’s 
relatives have been diagnosed with Familial 
Paroxysmal Hypokalaemic Paralysis. 
History of Presenting Complaint:
The patient occasionally suffers episodes of 
lower limb weakness. He takes potassium 
supplements during such episodes and 
symptoms resolve. 
Past Medical and Surgical History:
Past Medical History:
• anxiety
• folliculitis
• eczema
Past Surgical History: nil
Drug History and Allergies:
Allergies: 
Patient is allergic to cortisone injections
Family History: 
Grandfather, father and sister of patient are 
known to suffer from hypoKPP
The father tested positive for a known sequence 
variant in codon 58 of the CACNA1S gene.
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Social History:
The patient moved to Malta in 2018. He smokes 
occasionally, vapes and drinks two beers a 
week. He is married with no children and has a 
sedentary job.
Systemic Inquiry:
•General Health: patient looks well in general
•Cardiovascular System: no abnormalities
•Respiratory System: no abnormalities
•Gastrointestinal System: no abnormalities
•Genitourinary System: no lower urinary tract 
abnormalities
•Nervous System: no abnormalities; bilateral 
lower limb weakness and paralysis during 
hypokalaemic episodes only
•Musculoskeletal System: no abnormalities
•Endocrine System: no abnormalities
On Examination:
•Blood Pressure: 105/60 mmHg
•Pulse: 70 bpm
•CVS: S1 + S2
•chest clear
•abdomen: SNT
•LL: NAD
•ECG: NSR @ 72 bpm
Current Therapy for hypoKPP
The patient takes 6 tablets of K+ effervescent 
tablets daily to prevent hypokalaemic episodes.
Neurological Examination: 
Cranial Nerves: normal. no facial weakness
Inspection: no muscle wasting, scars or 
fasciculations 
Tone: normal
Power: normal
Reflexes: normal
Coordination: normal
Sensation: normal
Gait: normal
Differential Diagnosis:
•Hypokalaemic Periodic Paralysis (hypoKPP)
•Conn’s syndrome
•Cushing’s syndrome
•Thyrotoxic Periodic Paralysis (TPP)
Diagnostic Procedures:
Laboratory Exams:
Test: Referred for genetic testing for CACNA1S 
gene mutation
Justification for test: to confirm the presence of 
the gene mutation
Diagnosis:
Familial Paroxysmal Hypokalaemic Paralysis 
(hypoKPP)
Final Treatment and Follow Ups:
Continue same treatment.
Follow up with genetic result.
Fact Box
Title: Familial Paroxysmal Hypokalaemic 
Paralysis (hypoKPP)
Normal Physiology at the Neuromuscular 
Junction:
When an action potential reaches the axon 
terminal at the neuromuscular junction, voltage-
gated Ca2+ channels open, allowing Ca2+ ions to 
diffuse from the synaptic space into the motor 
axon. The Ca2+ ions activate Ca2+-calmodulin 
dependent protein kinase which phosphorylates 
synapsin proteins, freeing synaptic vesicles from 
the cytoskeleton in the process (Hall, 2016).
The acetylcholine molecules in the synaptic 
cleft attach to the muscle fibre membrane via 
acetylcholine-gated ion channels. In turn, the 
channel undergoes a conformational change, 
allowing Na+ ions to enter the muscle fibre and 
excite contraction. This action creates an end 
plate positive potential which gives rise to an 
action potential. The action potential spreads 
along the muscle membrane and causes muscle 
contraction (Hall, 2016).
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The usual structure and function of Ca2+ or Na+ 
channels are altered in hypoKPP. The mutated 
channels cannot effectively regulate flow of 
ions into muscle cells, leading to a disruption in 
ion transport. The ability of skeletal muscles to 
contract is reduced, giving rise to episodes of 
weakness and paralysis (Hall, 2016).
Definition and General Overview: Familial 
Hypokalaemic Paroxysmal Paralysis (hypoKPP) is 
a relatively rare channelopathy characterised by 
episodes of flaccid paralysis with concomitant 
hypokalaemia (serum [K+] <3.5 mmol/L). 
HypoKPP is correlated with significant 
morbidity, but rarely becomes life-threatening 
(Stapleton, 2018). 
The frequency of paralytic attacks is highest 
between age 15 and 35 and eventually 
decreases as the patient grows older. The 
duration of these attacks may vary from several 
hours to days (Statland et al., 2018).
Epidemiology: HypoKPP is an autosomal 
dominant condition with a prevalence of 
about 1 per 100,000 individuals. It has 90% 
penetrance in males and 50% penetrance in 
females. Indeed, genetic counselling is offered 
to individuals diagnosed with hypoKPP who are 
planning to have children (Stapleton, 2018).
Signs and Symptoms: The main features 
of hypoKPP include reduced muscle tone 
(flaccidity) proximally, normal to decreased 
deep tendon reflexes and bilateral muscle 
weakness during hypokalaemic episodes 
(Stapleton, 2018).
Causes: HypoKPP is mainly caused by 
pathogenic variants in the CACNA1S or SCN4A 
genes. In healthy subjects, these genes code 
for Ca2+ and Na+ ion channels respectively. 
It is estimated, however, that the associated 
genes are normal in 30% of hypoKPP patients 
(Statland et al., 2018).
In a study conducted by M. Castañeda et al., 
a missense mutation in the ATP1A2 gene was 
noted in a patient diagnosed with hypoKPP 
who had normal CACNA1A and SCN4A genes. 
This gene codes for the 2 subunit of the Na+/
K+-ATPase pump expressed in skeletal muscle 
cells and in brain astrocytes (Castañeda et al., 
2018).
Precipitating Factors: The consumption 
of carbohydrate-rich meals and rest after 
strenuous exercise are the most common 
triggers of acute flaccid paralysis due to the 
release of insulin and K+ influx into intracellular 
spaces, respectively. Other triggers include 
high-Na+ meals, cold temperatures, immobility, 
alcohol intake, anaesthetic procedures, fear and 
emotional stress (Stapleton, 2018).
Diagnosis: This is based on the patient’s clinical 
history, low serum K+ levels and family history of 
the condition (Stapleton, 2018). The diagnosis 
of hypoKPP is also based on criteria developed 
by the European Neuromuscular Centre 
(ENMC) International Workshop. If all four 
criteria are met, the individual is diagnosed with 
the channelopathy. It must be noted, however, 
that failure to satisfy all criteria does not rule 
out hypoKPP as a possible diagnosis (Stapleton, 
2018).
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Preventive Management: 
HypoKPP patients are advised to avoid 
common triggers, such as strenuous exertion. 
If avoidance is unsuccessful, prophylactic 
K+ replacement and/or carbonic anhydrase 
inhibitors are prescribed (Stapleton, 2018). 
In patients on life-long K+ prophylaxis, Mg2+ 
supplements promote renal retention of K+ 
ions, thereby enabling a reduction in the K+ 
dose (Statland et al., 2018).
K+-sparing diuretics are often prescribed to 
patients who have severe, recurrent attacks and 
remain unresponsive to carbonic anhydrase 
inhibitors (Stapleton, 2018).
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